참고문헌
- Abbruzzese JL, Abbruzzese MC, Hess KR, et al (1994). Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol, 12, 1272-80.
- Bocking A, Pomjansky N, Buckstegge B, et al (2009). Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies. Pathologe, 30, 158-60. https://doi.org/10.1007/s00292-009-1184-6
- Bonnefoi H, Smith IE (1996). How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer, 74, 832-5. https://doi.org/10.1038/bjc.1996.444
- Botte G, Laferrere L, Etchepare S, et al (1990). Diagnostic value of tumor markers in pleural effusions. Medicina, 50, 213-6.
- Cascinu S, Del Ferro E, Barbanti I, et al (1997). Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol, 20, 247-50. https://doi.org/10.1097/00000421-199706000-00007
- Cellerin L, Marcq M, Sagan C, et al (2008). Malignant pleural effusion as the presenting site of cancer: comparison with metastatic pleural effusions from known cancers. Rev Mal Respir, 25, 1104-9. https://doi.org/10.1016/S0761-8425(08)74980-5
- Cheng M, Chen Y, Yu X, et al (2008). Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer, 8, 156. https://doi.org/10.1186/1471-2407-8-156
- Davidson B, Baekelandt M, Shih IeM (2007). MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol, 35, 756-60. https://doi.org/10.1002/dc.20771
- Destombe C, Botton E, Le Gal G, et al (2007). Investigations for bone metastasis from an unknown primary. Joint Bone Spine, 74, 85-9. https://doi.org/10.1016/j.jbspin.2006.05.009
- Elstrand MB, Kleinberg L, Kohn EC, et al (2009). Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol, 28, 211-21. https://doi.org/10.1097/PGP.0b013e31818b0f5e
- Gaspar MJ, De Miguel J, Garcia Diaz JD, et al (2008). Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res, 28, 2947-52.
- Heffner JE, Nietert PJ, Barbieri C (2000). Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest, 117, 79-86. https://doi.org/10.1378/chest.117.1.79
- Jiang B, Wu GP, Zhao YJ, et al (2008). Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol, 36, 849-54. https://doi.org/10.1002/dc.20926
- Kwee TC, Takahara T, Ochiai R, et al (2008). Diffusionweighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol, 18, 1937-52. https://doi.org/10.1007/s00330-008-0968-z
- Kwee T C, Kwee RM (2009). Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol, 19, 731-44. https://doi.org/10.1007/s00330-008-1194-4
- Liang QL, Shi HZ, Qin XJ, et al (2008). Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta analysis. Thorax, 63, 35-41. https://doi.org/10.1136/thx.2007.077958
- Liu L, Cohen C, Siddiqui M T (2012). Thyroid transcription factor 1 and napsin a double staining in lung adenocarcinoma in pleural fluid. Acta Cytol, 56, 425-30. https://doi.org/10.1159/000337439
- Losa Gaspa F, Germa JR, Albareda JM, et al (2002). Metastatic cancer presentation. Validation of a diagnostic algorithm with 221 consecutive patients. Rev Clin Esp, 202, 313-9. https://doi.org/10.1016/S0014-2565(02)71065-5
- Malati T (2007). Tumour markers: An overview. Indian J Clin Biochem, 22, 17-31. https://doi.org/10.1007/BF02913308
- Panza N, Lombardi G, De Rosa M, et al (1987). High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer, 60, 2233-6. https://doi.org/10.1002/1097-0142(19871101)60:9<2233::AID-CNCR2820600922>3.0.CO;2-Y
- Pavlidis N, Kalef-Ezra J, Briassoulis E, et al (1994). Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol, 22, 162-7. https://doi.org/10.1002/mpo.2950220303
- Pavlidis N, Briasoulis E, Pentheroudakis G (2010). Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v228-31. https://doi.org/10.1093/annonc/mdq193
- Pomjanski N, Grote HJ, Doganay P, et al (2005). Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol, 33, 309-15. https://doi.org/10.1002/dc.20393
- Porcel JM, Vives M, Esquerda A, et al (2004). Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest, 126, 1757-63. https://doi.org/10.1378/chest.126.6.1757
- Pu RT, Giordano TJ, Michael CW (2008). Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation. Cancer, 114, 300-6. https://doi.org/10.1002/cncr.23797
- Roberts ME, Neville E, Berrisford RG, et al (2010). Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 65, ii32-40.
- Sears D, Hajdu SI (1987). The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol, 31, 85-97.
- Shitrit D, Zingerman B, Shitrit AB, et al (2005). Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist, 10, 501-7. https://doi.org/10.1634/theoncologist.10-7-501
- SUN Yongchang, HU Hong, XIA Guoguang, XU Wenbing, WANG Hongwu (2011). An invesigation on diagnosis of pleural effusions in some teaching hospitals at Beijing district. Chin J Tube Resp Dise, 34, 233-.
- Tsukushi S, Katagiri H, Kataoka T, et al (2006). Serum tumor markers in skeletal metastasis. Jpn J Clin Oncol, 36, 439-44. https://doi.org/10.1093/jjco/hyl046
- van de Molengraft FJ, Vooijs GP (1989). Survival of patients with malignancy-associated effusions. Acta Cytol, 33, 911-6.
- Watanabe N (1996). Organ specificity of tumor markers and its application for clinical diagnosis. Nihon Rinsho, 54, 1592-6.
- Zhu W, Michael CW (2007). WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol, 35, 370-5. https://doi.org/10.1002/dc.20643
피인용 문헌
- Utility of Nuclear Morphometry in Effusion Cytology vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6919
- Tumor Markers in Serum and Ascites in the Diagnosis of Benign and Malignant Ascites vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.719
- Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer vol.107, pp.9, 2016, https://doi.org/10.1111/cas.12987
- Pleural fluid carcinoembryonic antigen as a biomarker for the discrimination of tumor-related pleural effusion vol.11, pp.6, 2016, https://doi.org/10.1111/crj.12431
- Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion vol.37, pp.3, 2016, https://doi.org/10.1007/s13277-015-4174-8
- Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis vol.22, pp.2, 2017, https://doi.org/10.1007/s10147-016-1073-y